Over the past several decades, the frequency of. Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years. Ronald N.

Transcription

1 Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years Ronald N. Jones, MD Multiple surveillance studies have demonstrated that resistance among prevalent pathogens is increasing at an alarming rate, leading to greater patient morbidity and mortality from nosocomial infections. Among Gram-positive organisms, the most important resistant pathogens are methicillin- (oxacillin-)resistant Staphylococcus aureus, -lactam-resistant and multidrugresistant pneumococci, and vancomycin-resistant enterococci. Important causes of Gram-negative resistance include extended-spectrum -lactamases (ESBLs) in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis, high-level third-generation cephalosporin (Amp C) -lactamase resistance among Enterobacter species and Citrobacter freundii, and multidrugresistance genes observed in Pseudomonas aeruginosa, Acinetobacter, and Stenotrophomonas maltophilia. In selecting an empiric treatment for a nosocomial infection, one should consider the prevalent resistance patterns. Antimicrobials used for the treatment of nosocomial infections should be effective against any likely resistant pathogens and should not further promote the development of resistance. Recent data suggest that because of ESBLs and high-level amp C -lactamase resistances, use of third-generation cephalosporins may be ineffective in many patients with nosocomial infections. In addition, use of these agents may allow overgrowth of inherently resistant enterococci. The role of fluoroquinolones in the empiric treatment of nosocomial infections is also being limited by new resistance patterns and increasing resistance levels. Available antimicrobials with good activity against many resistant pathogens include the carbapenems, piperacillin/tazobactam, and cefepime. In addition, several new agents with good activity against Gram-positive organisms are in development or have been recently released. Appropriate antimicrobial selection, surveillance systems, and effective infection-control procedures are key partners in limiting antimicrobial-resistant pathogen occurrence and spread. (CHEST 2001; 119:397S 404S) Key words: antibiotic resistance; antibiotics; cephalosporins; enterococci; fluoroquinolones; methicillin-resistant Staphylococcus aureus; nosocomial infections; penicillins; pneumococci Abbreviations: ESBL extended-spectrum -lactamase; MRSA methicillin-resistant Staphylococcus aureus; PBP penicillin-binding protein; SCOPE Surveillance and Control of Pathogens of Epidemiological Importance; VRE vancomycin-resistant enterococci Over the past several decades, the frequency of antimicrobial resistance and its association with serious infectious diseases have increased at alarming rates. The increasing resistance rate among nosocomial pathogens is particularly disconcerting. Of the 2 million nosocomial infections occurring each year in the United States, 50 to 60% are caused by antimicrobial-resistant strains of bacteria. 1 This high rate of resistance increases the morbidity, *From the Department of Pathology, University of Iowa College of Medicine, Iowa City, IA. Correspondence to: Ronald N. Jones, MD, The Jones Group, 345 Beaver Kreek Centre, Suite A, North Liberty, IA mortality, and costs associated with nosocomial infections. 2 In the United States, nosocomial infections are thought to contribute to or cause 77,000 deaths per year and cost approximately $5 to $10 billion annually. 1 3 Expert panels have concluded that surveillance networks, education of health-care providers and the public, and basic research directed toward development of new methods of infection treatment and prevention are required to address the problem of antimicrobial resistance. 4 This review will summarize the recent findings of several surveillance networks and discuss the impact of current patterns of antimicrobial resistance on the selection of antimicrobials for the empiric therapy of nosocomial infections, particularly lower-respiratory-tract infections. CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 397S

2 Trends in Nosocomial Infections Numerous surveillance studies have documented trends in nosocomial infections that might affect resistance patterns. For example, the National Nosocomial Infections Surveillance group 1 found that from 1975 to 1996, the percentage of nosocomial infections that occurred in the lower respiratory tract or bloodstream increased while the percentage that occurred in the urinary tract or in surgical wounds decreased. From 1990 to 1996, the lower respiratory tract and the bloodstream were sites of nosocomial infections 13% and 14% of the time, respectively. This indicates a greater shift toward more severely ill patients, as well as the positive impact of infection control in limiting urinary tract and postoperative infections in those who are hospitalized. Changes in the types of pathogens isolated in serious infections might also affect resistance patterns because different bacterial species inherently have differing antimicrobial susceptibilities. 4 The European Organization for Research and Treatment of Cancer trials, which were performed between 1973 and 1994, documented trends in the types of pathogens isolated from oncology patients with febrile morbidities. While Gram-negative pathogens were the dominant bloodstream isolates from 1973 to 1985, Gram-positive isolates were more common in later years. 5 This change in pathogen dominance coincided with the 1985 introduction of the thirdgeneration cephalosporins ceftazidime and ceftriaxone and was probably driven by the widespread use of these drugs. 6 The European Organization for Research and Treatment of Cancer trials also documented changes in the species of Gram-positive organisms that were isolated. Over time, a larger percentage of the Gram-positive organisms isolated were Streptococcus, particularly -hemolytic streptococci and viridans groups, replacing formerly more commonplace staphylococcal isolates. 5 7 The international SENTRY Antimicrobial Surveillance Program 8 is also documenting trends in the occurrence of pathogens that are related to altered resistance patterns. This program, which was initiated in 1997 and has 70 sites worldwide, is a longitudinal surveillance program designed to track antimicrobial resistance patterns of nosocomial and community-acquired infections. As shown in Table 1, the program reported that Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae were the most common causes of pneumonia in hospitalized patients in North America in 1997 (R.N. Jones, MD; unpublished data; 2000). Acinetobacter, an organism that has been particularly problematic in Latin America where it is the third-most-prevalent pathogen because of the high frequency at Table 1 Frequency of Occurrence of Bacterial Pathogens Causing Pneumonias in Hospitalized Patients in the United States and Canada (SENTRY Antimicrobial Surveillance Program, 1997)* Organisms Percent of Total United States Canada Combined S aureus P aeruginosa H influenzae Klebsiella S pneumoniae Enterobacter E coli S maltophilia M catarrhalis Serratia marcescens *Unpublished data (R.N. Jones, MD; 1999). which it is isolated and its high rate of resistance, 9 was ranked as the 10th most common cause of pneumonia in hospitalized patients in the United States and Canada. The SENTRY Antimicrobial Surveillance Program also found that S aureus, Escherichia coli, coagulase-negative staphylococci, Enterococcus, Klebsiella, Streptococcus pneumoniae, P aeruginosa, Enterobacter, -hemolytic streptococci, and Acinetobacter were the 10 most common bacterial pathogens responsible for bloodstream infections in the United States and Canada in Gram-Positive Resistance Of primary importance among Gram-positive pathogens today are vancomycin-resistant enterococci (VRE), -lactam-resistant and multidrug-resistant streptococci, and methicillin-resistant S aureus (MRSA). Over the past decade, surveillance programs have repeatedly documented an increase in each of these types of resistance. From 1990 to 1997, the prevalence of VRE increased from 1% to approximately 15%; the rate of vancomycin-resistant staphylococci remains quite rare. 4,10,11 While the rate of penicillin resistance among pneumococci was 4% in 1990, by 1997, penicillin resistance had increased to approximately 30 to 50% of pneumococci. In 1990, 20 to 25% of S aureus isolates were methicillin resistant and, in 1997, the rate reached 25 to 50%. Enterococcal Resistance Enterococcal antimicrobial resistance, particularly VRE, is a serious concern. Multiple vancomycin resistance phenotypes have been identified, includ- 398S Hospital-Acquired Infections: Realities of Risks and Resistance

3 ing van A, van B, and van C. The van A gene, which is often plasmid borne, confers high-level resistance to vancomycin and can be transferred to other micro-organisms. 12 The rate of vancomycin resistance varies among enterococcal species and is most common among Enterococcus faecium. 4 Studies 8,11,13 have documented that VRE are most commonly isolated from highly compromised patients, such as those in the ICU. Other types of enterococcal resistance include -lactamase-mediated resistance, ampicillin resistance based on altered penicillin-binding proteins (PBPs), and high-level aminoglycoside resistance. Among enterococcal organisms, -lactamase-mediated resistance is currently very rare ( 0.1%). Ampicillin resistance owing to PBP changes is much more common and occurs in 80% of E faecium clinical isolates and in 5% of Enterococcus faecalis. While the rate of high-level aminoglycoside resistance varies markedly among institutions, the nationwide prevalence is estimated at 30 to 60%. Some enterococcal species are also highly resistant to macrolides, fluoroquinolones, tetracyclines, and carbapenems. 4,10 Table 2 shows the resistance patterns of various enterococcal species as reported by the Surveillance and Control of Pathogens of Epidemiological Importance (SCOPE) program. 4 E faecalis, which causes approximately 60% of nosocomial bloodstream infections, is associated with low rates of vancomycin, teicoplanin, and penicillin resistance and higher rates of gentamicin resistance. E faecium, which causes approximately 20% of nosocomial enterococcal bloodstream infections, is much more commonly associated with vancomycin, teicoplanin, penicillin, and high-level gentamicin resistance. Greater than 85% of E faecium isolates are resistant to penicillin, and 50% are resistant to high-level gentamicin. The highest rates of enterococcal resistance were reported with Enterococcus raffinosus, which fortunately is rarely isolated. 4 While no resistance was noted among some uncommon enterococcal species in the SCOPE study, vancomycin resistance genes from E faecium and E faecalis have been shown to transfer to other rare enterococcal species; however, it is important to note that identification of such rare species may be difficult using commercial identification systems. 14 Geographic location appears to influence the prevalence of VRE. In the SCOPE study, the number of sites reporting VRE varied across the United States: 60% of Southwest sites, 44% of Southeast sites, 39% of Northeast sites, and 11% of Northwest sites reported at least one VRE isolate. The frequencies at which VRE strains were isolated were 21%, 11%, 11%, and 9.5% in the Northeast, Southeast, Southwest, and Northwest, respectively. While the van A genotype predominates in the Northeast and Southwest, the van A and van B genotypes occured at an equal rate in the Northwest and Southeast. 4 The rate of VRE occurrence is also influenced by the site of infection. Among US centers that participated in the 1997 SENTRY Antimicrobial Surveillance Program, the rate of VRE was 19.3%, 16.3%, 8.7%, and 6.1% in wound, bloodstream, lung (pneumonia), and urinary tract infections, respectively (R.N. Jones, MD; unpublished data; 1999). Although the rate of resistance in urinary tract infections was low, the greatest absolute number of VRE strains were isolated from the urine because enterococcal urinary tract infections are so common. Since VRE infections are associated with much higher morbidity and mortality than are vancomycinsensitive enterococcal infections, 15 and since vancomycin resistance genes may be transmitted to other species, 16 it is important to limit VRE. Recommendations for controlling vancomycin resistance include reducing the use of drugs known to increase the risk of enterococcal infection (eg, third-generation cephalosporins), limiting vancomycin use, applying Table 2 Resistance Patterns Among Enterococcal Organisms Isolated From Bloodstream Infections (SCOPE Study, )* Percent Susceptible Organisms (No. Tested) Vancomycin Teicoplanin Penicillin High-Level Gentamicin E faecalis (288) E faecium (96) Enterococcus (79) E raffinosus (7) Enterococcus durans (3) Enterococcus avium (2) Enterococcus gallinarum (2) Enterococcus casseliflavus (1) *Data from Jones and Pfaller. 4 CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 399S

4 accurate microbiological identification methods and susceptibility testing methods, conducting epidemiologic surveillance, using barrier precautions, and maintaining strict hand-washing policies. 4,12 Empiric treatment of nosocomial infections with broad-spectrum agents that provide good enterococcal coverage (eg, a penicillin with a -lactamase inhibitor such as piperacillin/tazobactam), may decrease the risk of enterococcal colonization and resistance. It is important to note, however, that the antimicrobial activity of penicillins against enterococcal species varies: penicillin, ampicillin, and piperacillin are much more active than ticarcillin. 17,18 Pneumococcal Resistance The rate of penicillin resistance among pneumococci has reached crisis proportions. Treatment of pneumococcal infections is further complicated by an increasing rate of resistance to macrolides, cephalosporins, chloramphenicol, tetracyclines, trimethoprim/sulfamethoxazole, and most recently fluoroquinolones. 19,20 Penicillin and cephalosporin resistance is mediated by multiple alterations in PBPs. Depending on the targeted PBP, penicillinresistant organisms may or may not be susceptible to other -lactams. Table 3 provides the penicillin susceptibility pattern obtained in the SENTRY Antimicrobial Surveillance Program of S pneumoniae isolates to several antimicrobial agents. 21 Various studies have examined the efficacy of fluoroquinolones in the treatment of pneumococcal infections. Trovafloxacin and grepafloxacin, although now rarely used, appear to have the greatest potency Table 3 S pneumoniae Antimicrobial Resistance Indexed by Penicillin Susceptibility (SENTRY Antimicrobial Surveillance Program, 1997)* Antimicrobial Agents Resistance Rates by Penicillin Susceptibility Pattern Susceptible (%) Intermediate (%) Resistant (%) Cefaclor Cefuroxime Cefpodoxime Cefotaxime Cefepime Erythromycin Clindamycin Trimethoprim/sulfamethoxazole *Data from Doern et al. 21 Susceptible at 0.06 g/ml; intermediate at 0.12 to 1.0 g/ml; and resistant at 2.0 g/ml of penicillin. Percent resistance to listed drug among isolates having various categorical susceptibility patterns to penicillin. followed by sparfloxacin, gatifloxacin, ciprofloxacin, and levofloxacin. 22 However, recent data have demonstrated that a small number (0.1 to 0.2%) of pneumococci are highly resistant to all fluoroquinolones, regardless of their potency. 20,22 Presence of this global fluoroquinolone resistance does not correlate with the presence of penicillin resistance in some studies. 20 Aside from some quinolones, antimicrobial agents that may be effective against penicillin-resistant pneumococci include third-generation and fourth-generation cephalosporins, carbapenems, vancomycin, and teicoplanin. 4,8,20,23 Staphylococcal Resistance Since staphylococci are commonly responsible for nosocomial infections, particularly pneumonia, resistance among these organisms is also a major concern. 1 Both methicillin (or oxacillin) and glycopeptide (vancomycin and teicoplanin) resistance may occur in staphylococci. A European study demonstrated that 50% of the infectious morbidity in ICUs can be attributed to MRSA or coagulase-negative staphylococci. 13,24 Currently, the most prevalent type of resistance among staphylococci is methicillin resistance. This resistance is encoded genetically by mec A, which produces an altered PBP target. 4 In the 1997 SENTRY program, MRSA was isolated from 26.9%, 49.8%, 29.0%, and 48.0%, of hospitalized patients in the United States with bloodstream, pneumonia, wound, and urinary tract infections, respectively (R.N. Jones, MD; unpublished data; 1999). While the rates of resistance were much lower in Canada, they were substantially higher in Latin America. The relatively low rate of MRSA in Canada is likely the result of formulary controls limiting the choice of available antimicrobials; superior infection control practices also appeared to play a significant role. Since MRSA is also resistant to many other antimicrobials, both -lactams and non- -lactams, 8 vancomycin is generally relied on for the treatment of MRSA infections. However, the expanded use of vancomycin has led to the emergence of other resistance problems. 4,25 Similarly, when ciprofloxacin was initially introduced to the market, it was highly effective against MRSA. However, almost immediately after release by the US Food and Drug Administration, studies in the United States showed significant increases in the minimum inhibitory concentrations of ciprofloxacin against staphylococci, especially against MRSA. 26 The rare reports of glycopeptide-resistant S aureus are also alarming. Teicoplanin-resistant coagulasenegative staphylococci were first reported in 1985; in 400S Hospital-Acquired Infections: Realities of Risks and Resistance

5 1987, vancomycin-resistant coagulase-negative staphylococci were reported. 7 Since the initial report from Japan in 1997, 25 many other groups from around the world have reported strains of S aureus with intermediate resistance to vancomycin. All of the reported cases occurred in patients who had prolonged ( 1 month) exposure to vancomycin. Gram-Negative Resistance Antimicrobial resistance among Gram-negative organisms is also a concern. The most important Gram-negative resistance problems that impact on nosocomial infections are extended-spectrum -lactamases (ESBLs) in Klebsiella pneumoniae, E coli, and Proteus mirabilis; high-level third-generation cephalosporin (Amp C) -lactamase resistance among Enterobacter and Citrobacter freundii; and multidrug-resistant P aeruginosa, Acinetobacter, and Stenotrophomonas maltophilia. 4 The treatment of respiratory tract infections is also complicated by -lactamase production among H influenzae and Moraxella catarrhalis. 4 However, over the past 3 to 5 years, the rates of resistance of H influenzae and M catarrhalis have remained stable at approximately 33% and 90%, respectively. 24 While the rate of K pneumoniae resistance to third-generation and fourth-generation cephalosporins due to ESBLs is also fairly stable, it remains an important problem in patients with nosocomial infections. 4 In 1997, the SENTRY Antimicrobial Surveillance Program found that, among K pneumoniae strains isolated in the United States, the resistance rates to ceftazidime (as well as ceftriaxone and cefotaxime) were 6.6%, 9.7%, 5.4%, and 3.6% for bloodstream, pneumonia, wound, and urinary tract infections, respectively (R.N. Jones, MD; unpublished data; 1999). Substantially higher resistance rates were noted in some of the individual hospitals enrolled in the study, and resistance rates of 30 to 50% were observed in the Latin American institutions studied. 9 Also, resistance of K pneumoniae strains to ceftriaxone has been reported in epidemics. 27,28 Alternative antimicrobials that may be considered for use in patients with infections due to ESBLproducing strains of K pneumoniae include -lactamase inhibitor combinations, such as piperacillin/ tazobactam, and carbapenems. 4 Cross-resistance may limit the value of aminoglycosides, tetracyclines, and trimethoprim/sulfamethoxazole in these types of infections. 4 Fluoroquinolone resistance is also increasing among these ESBL strains. High-level amp C -lactamase resistance should also be considered when treating nosocomial infections. In 1997, the SENTRY Antimicrobial Surveillance Program noted that among Enterobacter cloacae bloodstream strains isolated in the United States, the resistance rate to ceftazidime was 21.6%. 6 These rates reflected a stabilization of the prevalence of high-level amp C -lactamase resistance among E cloacae. The corresponding resistance rate for cefepime was only 0.5%, the same as imipenem. 6 Therefore, these newer -lactams may have some utility in the treatment of infections due to amp C enzyme-producing resistant organisms. Other agents with activity against these resistant organisms include meropenem, other carbapenems, aminoglycosides, and fluoroquinolones. 4,6 The rate of fluoroquinolone resistance among Gram-negative organisms continues to escalate. In the 1997 SENTRY Antimicrobial Surveillance Program, 2.1% of E coli, 13.3% of P aeruginosa, 24.1% of Acinetobacter, and 48.5% of S maltophilia isolates obtained in the United States were resistant to ciprofloxacin. 6 Furthermore, in the subgroup of patients with lower-respiratory-tract infections, 1.1% of E coli, 16.3% of P aeruginosa, 37.7% of Acinetobacter, and 42.7% of S maltophilia isolates from the United States and Canada were resistant to ciprofloxacin (R.N. Jones; unpublished data, 1999). The rates of ciprofloxacin resistance are substantially higher in Latin America. In addition, the 1998 SENTRY Antimicrobial Surveillance Program data demonstrate that an even higher percentage of P aeruginosa strains isolated from lower-respiratorytract infections are resistant to the newer fluoroquinolones (R.N. Jones; unpublished data, 2000). Table 4 demonstrates the in vitro susceptibility of P aeruginosa to other classes of antimicrobials. Of the various cell wall inhibitors examined, piperacillin/tazobactam had the lowest level of resistance. Table 4 In Vitro Susceptibility of 488 P aeruginosa Isolates From Lower-Respiratory-Tract Infections (SENTRY Antimicrobial Surveillance Program, 1998)* Antimicrobials Percent Susceptible Cefepime 82 Ceftazidime 78 Imipenem 79 Piperacillin 86 Piperacillin/tazobactam 88 Ticarcillin/clavulanate 69 Ciprofloxacin 74 Levofloxacin 67 Ofloxacin 55 Trovafloxacin 64 Amikacin 94 Gentamicin 81 Tobramycin 90 *Adapted from SENTRY Antimicrobial Surveillance Program results. CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 401S

6 Ticarcillin/clavulanate was less effective than piperacillin/tazobactam, confirming earlier results. 17,18 Among the protein synthesis inhibitors, amikacin appeared to be the agent with the lowest level of P aeruginosa resistance. New Antimicrobials Research is under way to develop new antimicrobial agents that are effective against the increasing number of resistant organisms. The majority of the promising compounds in development are directed against Gram-positive organisms These compounds include streptogramin combinations (quinupristin/dalfopristin), 31 ketolides (HMR-3647, ABT- 773), everninomicin derivatives (evernimicin or SCH 27899, recently withdrawn from clinical trials), 30 oxazolidinones (linezolid and eperezolid), 29 glycopeptides (LY ), glycylcyclines (GAR-936), and additional fluoroquinolones (gemifloxacin, moxifloxacin, sitafloxacin). Table 5 lists the minimum inhibitory concentrations of some of these agents against problematic Gram-positive species. Based on these preliminary data, quinupristin/dalfopristin and linezolid appear to be very promising in the treatment of Gram-positive infections, both of which are now available for clinical use. While the newer fluoroquinolones show promise for the treatment of pneumococcal infections, the 0.1 to 0.2% rate of high-level resistance of pneumococci to fluoroquinolones described earlier seems to apply to some of the newer fluoroquinolones. Furthermore, although the newer fluoroquinolones also have Gram-negative coverage, they are not as potent against these organisms as is ciprofloxacin. Conclusion Antimicrobial surveillance programs have documented troublesome rates of emerging resistance among prevalent pathogens, especially Gram-positive species. Since a high percentage of nosocomial infections are caused by resistant organisms, antimicrobials used for the treatment of nosocomial infections must have a balanced and reliable spectrum of activity against these pathogens. Many drugs that have frequently been used in the past as empiric therapy have become less effective against nosocomial pathogens. For example, ceftazidime has experienced a continued decline in its spectrum as a result of decreased potency against penicillin-resistant S pneumoniae, viridans group streptococci, ESBL-producing enteric bacilli, and high-level amp C -lactamase-producing Enterobacter and Citrobacter. Rapidly emerging resistance is also compromising the effectiveness of older fluoroquinolones. While new fluoroquinolones appear to have more utility against Gram-positive organisms, they can have lower activity than ciprofloxacin against P aeruginosa. There are, however, some antimicrobials with good activity against resistant organisms. For example, the carbapenems, piperacillin/tazobactam, and cefepime cover methicillin-susceptible staphylococci, most streptococci, nearly all enterobacteriaceae, and significant numbers of P aeruginosa, S maltophilia, and Acinetobacter, as indicated by data 8 from North America. When selecting empiric antimicrobial therapy for nosocomial infections, combinations of drugs that provide effective broad Gram-negative activity and focused Gram-positive activity, as demonstrated by local antimicrobial surveillance, seem preferred. Careful drug selection coupled with surveillance and effective infection control procedures may help control pathogen resistance. Appendix Dr. Thomas File: Do you support the use of disease-based breakpoints? For example, using a breakpoint of 2 mg/l for S pneumoniae isolates responsible for pneumonia? Dr. Ronald Jones: Yes, I think in the near future the Table 5 In Vitro Activity of New Antimicrobial Agents Against Problematic Gram-Positive Species* MIC 90, g/ml Susceptible Breakpoint Pathogens Resistance Linezolid ( 4 g/ml) Quinupristin/ Dalfopristin ( 1 g/ml) SCH ( 4 g/ml) Trovafloxacin ( 1 g/ml) E faecium Vancomycin S aureus Oxacillin S pneumoniae Penicillin *From Jones et al MIC minimum inhibitory concentration for 90% of isolates. 402S Hospital-Acquired Infections: Realities of Risks and Resistance

7 National Committee for Clinical Laboratory Standards will recommend that the current system for pneumonia, which bases all breakpoints on the treatment of a closed-space infection (eg, meningitis), will be replaced by a system that includes multiple disease-based breakpoints. Based on the available data, a breakpoint of 2 mg/l indicating susceptible ( 0.06 ml for meningitis) for penicillin does appear appropriate for S pneumoniae isolates responsible for pneumonia. Dr. Joseph Lynch: Given the high rate at which MRSA is isolated from patients with pneumonia, do you recommend the empiric use of vancomycin for pneumonia in ICU patients? Dr. Jones: I am a pathologist and a microbiologist, but I do think these data will drive clinicians to use more vancomycin or newer alternatives in these patients. Dr. John Segretti: How effective are aminoglycosides in the treatment of MRSA? Dr. Jones: Approximately 10% of our patients have coresistance to gentamicin. Other hospitals have reported tobramycin resistance in as many as 20% of isolates. Local information is essential to select the best aminoglycoside combination therapy. Dr. Michael Miller: I have observed clinically that aminoglycosides do not work in the treatment of many deep-seated staphylococcal infections. I think their lack of clinical efficacy is due to the following: (1) selection of small colony areas that are very unstable, and (2) aminoglycoside uptake being a voltage-gated phenomenon driven by ph and anaerobic conditions. References 1 Weinstein RA. Nosocomial infection update. Emerg Infect Dis 1998; 4: Public Health Initiative Research Institute. Report from the Bacterial Antibiotic Resistance Group/Infectious Disease Center. Washington, DC: US Government Printing Office, US Department of Health and Human Services. Addressing emerging infectious disease threats: a prevention strategy for the United States. Washington, DC: US Government Printing Office, Jones RN, Pfaller MA. Bacterial resistance: a worldwide problem. Diagn Microbiol Infect Dis 1998; 31: Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41(suppl D): Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in Gram-positive bacteria: enterococci, staphylococci and nonpneumococcal streptococci. Drugs 1996; 51(suppl 1): Pfaller MA, Jones RN, Doern GV, et al, for the Sentry Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: Sader HS, Jones RN, Gales AC, et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997): SENTRY Latin America Study Group. Diagn Microbiol Infect Dis 1998; 32: Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to Gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999; 33: Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin United States, MMWR Morb Mortal Wkly Rep 1993; 42: Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1994; 44: Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: Wilke WW, Marshall SA, Coffman SL, et al. Vancomycinresistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program. Diagn Microbiol Infect Dis 1997; 28: Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycinresistant Enterococcus faecium or vancomycin-susceptible E faecium. Clin Infect Dis 1996; 22: Noble WC, Virani Z, Cree RGA. Cotransfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC to Staphylococcus aureus. FEMS Microb Lett 1992; 93: Jones RN, Pfaller MA, Fuchs PC, et al. Piperacillin/tazobactam (YTR 830) combination: comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis 1989; 12: Murray PR, Cantrell HF, Lankford RB, for the In Vitro Susceptibility Surveillance Group. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected -lactam antibiotics and ciprofloxacin against more than 42,000 aerobic Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 1994; 19: Doern GV, Brueggemann AB, Blocker M, et al. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis 1998; 27: Jones RN, Pfaller MA, Doern GV. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the respiratory infection season; Diagn Microbiol Infect Dis 1998; 32: CHEST / 119 / 2/ FEBRUARY, 2001 SUPPLEMENT 403S

8 21 Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27: Odland BA, Jones RN, Verhoef J, et al. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. Diagn Microbiol Infect Dis 1999; 34: Klugman KP. Activity of teicoplanin and vancomycin against penicillin-resistant pneumococci. Eur J Clin Microbiol Infect Dis 1994; 13: Jones RN. The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections. Am J Health Syst Pharm 1999; 56:S4 S11 25 Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: Ena J, Houston A, Wenzel RP, et al. Trends in Gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital. J Chemother 1993; 5: Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: Monnet DL, Biddle JW, Edwards JR, et al. Evidence of interhospital transmission of extended-spectrum lactamresistant Klebsiella pneumoniae in the United States, 1986 to Infect Control Hosp Epidemiol 1997; 18: Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U and U , two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996; 40: Jones RN, Barrett MS. Antimicrobial activity of SCH 27899, oligosaccharide member of the enerninomycin class with a wide Gram-positive spectrum. Clin Microbial Infect 1995; 1: Jones RN, Ballow CH, Biedenbach DJ, et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid ) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31: S Hospital-Acquired Infections: Realities of Risks and Resistance